Please click below to access the 2021 Clinical Neuromuscular Pathology reading list.
The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content.
To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within ten business days of passing the quiz.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.
The UCNS complies with all standards and policies of the ACCME, including identiﬁcation and resolution of all conﬂicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS planners, authors, and staff comply with the UCNS’s Conﬂicts of Interest Policy.
P. James B. Dyck, MD, FAAN, Chair, Mayo Clinic – Rochester
Disclosures: Receives fees from Akcea pharmaceutical for speaking about TTR amyloid neuropathy.
Andrea M. Corse, MD, Vice Chair, Johns Hopkins Hospital
Disclosures: Received research funding from Biogen to present A Phase I, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults with C9ORF72-Associated Amyotrophic Lateral Sclerosis.
Robert C. Bucelli, MD, PhD, Washington University School of Medicine
Disclosures: Receives research support from Biogen for multiple ALS ASO trials at Washington University. Role: Principal investigator.
Mazen Mohammad Dimachkie, MD, University of Kansas Medical Center
Disclosures: Serves as a paid consultant for ArgenX, Catalyst, CSL-Behring, Kezar, Momenta, NuFactor, RMS Medical, Sanofi Genzyme, Shire Takeda, and Spark Therapeutics; received research grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Sanofi Genzyme, Octapharma, Orphazyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed & TMA.
Ahmed Mohamed Attia El-Dokla, MD, Neuromuscular Clinic at Upstate Bone & Joint
Disclosures: Nothing to disclose.
Shalini Mahajan, MD, Cedars-Sinai Medical Center
Disclosures: Nothing to disclose.
Raghav Govindarajan, MD, University of Missouri
Disclosures: Received compensation from Alexion MT PHARMA Catalyst PHARMA Argenx Infucare; received publication fees from Springer Publishing; research support received from Ra PHARMA Alexion Dysimmune foundation Band of Hope foundation.
Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Receives compensation for serving as associate editor of Neurology Genetics; Receives research funding by Mayo Clinic benefactor.
Michelle Lynn Mauermann, MD, Mayo Clinic – Rochester
Disclosures: Receives research support from Alnylam for TTR amyloid clinical trial and from IONIS for TTR amyloid clinical trial.
Aziz Shaibani, MD, Nerve and Muscle Center of Texas
Disclosures: Received compensation to serve on Stealth BioTherapeutics advisory board regarding primary mitochondrial myopathy (PMM) and elamipretide.
Bryan Hagerla, Continuous Certification Manager